These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 26487443)

  • 1. The greedy nature of mutant RAS: a boon for drug discovery targeting cancer metabolism?
    Lv J; Wang J; Chang S; Liu M; Pang X
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):17-26. PubMed ID: 26487443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the RAS-dependent chemoresistance: The Warburg connection.
    Serna-Blasco R; Sanz-Álvarez M; Aguilera Ó; García-Foncillas J
    Semin Cancer Biol; 2019 Feb; 54():80-90. PubMed ID: 29432815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
    Fang B
    Acta Biochim Biophys Sin (Shanghai); 2016 Jan; 48(1):27-38. PubMed ID: 26350096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K/Akt/mTOR and Ras/Raf/MEK/ERK signaling pathways inhibitors as anticancer agents: Structural and pharmacological perspectives.
    Asati V; Mahapatra DK; Bharti SK
    Eur J Med Chem; 2016 Feb; 109():314-41. PubMed ID: 26807863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Past, Present, and Future of Targeting Ras for Cancer Therapies.
    Tan Z; Zhang S
    Mini Rev Med Chem; 2016; 16(5):345-57. PubMed ID: 26423695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluating The Role Of Nitric Oxide Synthase In Oncogenic Ras-Driven Tumorigenesis.
    Counter C
    Redox Biol; 2015 Aug; 5():417. PubMed ID: 28162280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic Dependencies in RAS-Driven Cancers.
    Kimmelman AC
    Clin Cancer Res; 2015 Apr; 21(8):1828-34. PubMed ID: 25878364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting the bad eating habits of Ras-driven cancers.
    White E
    Genes Dev; 2013 Oct; 27(19):2065-71. PubMed ID: 24115766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.
    Milosevic Z; Pesic M; Stankovic T; Dinic J; Milovanovic Z; Stojsic J; Dzodic R; Tanic N; Bankovic J
    Transl Res; 2014 Nov; 164(5):411-23. PubMed ID: 25016932
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IκBα kinase inhibitor BAY 11-7082 promotes anti-tumor effect in RAS-driven cancers.
    Guruvaiah P; Gupta R
    J Transl Med; 2024 Jul; 22(1):642. PubMed ID: 38982514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase.
    Toda K; Kawada K; Iwamoto M; Inamoto S; Sasazuki T; Shirasawa S; Hasegawa S; Sakai Y
    Neoplasia; 2016 Nov; 18(11):654-665. PubMed ID: 27764698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving Prospects for Targeting RAS.
    Singh H; Longo DL; Chabner BA
    J Clin Oncol; 2015 Nov; 33(31):3650-9. PubMed ID: 26371146
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS and BRAF: drug targets and predictive biomarkers.
    Vakiani E; Solit DB
    J Pathol; 2011 Jan; 223(2):219-29. PubMed ID: 21125676
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in Ras therapeutics in pancreatic cancer.
    Choi M; Bien H; Mofunanya A; Powers S
    Semin Cancer Biol; 2019 Feb; 54():101-108. PubMed ID: 29170065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ras proteins as therapeutic targets.
    Chakraborty A; Linnane E; Ross S
    Biochem Soc Trans; 2018 Oct; 46(5):1303-1311. PubMed ID: 30154091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Wild-type H- and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response.
    Grabocka E; Pylayeva-Gupta Y; Jones MJ; Lubkov V; Yemanaberhan E; Taylor L; Jeng HH; Bar-Sagi D
    Cancer Cell; 2014 Feb; 25(2):243-56. PubMed ID: 24525237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting autophagy to overcome drug resistance in cancer therapy.
    Kumar A; Singh UK; Chaudhary A
    Future Med Chem; 2015 Aug; 7(12):1535-42. PubMed ID: 26334206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.